Skip to main content
SpringerLink
Log in

Medical costs of surgical intervention for hospitalized patients with neurofibromatosis type 1 in Japan

  • Correspondence
  • Published:
European Journal of Dermatology

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Yoshida Y, Ehara Y, Koga M, Imafuku S, Yamamoto O. Epidemiological analysis of major complications requiring medical intervention in patients with neurofibromatosis 1. Acta Derm Venereol 2018; 98: 753–6.

    Article  Google Scholar 

  2. Dombi E, Baldwin A, Marcus LJ, et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med 2016; 375: 2550–60.

    Article  CAS  Google Scholar 

  3. Espírito Santo V, Passos J, Nzwalo H, et al. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience. J Neurooncol 2020; 147: 459–63.

    Article  Google Scholar 

  4. Passos J, Nzwalo H, Azevedo M, Tavares M, Nunes S. Dramatic improvement of a massive plexiform neurofibroma after administration of selumetinib. Pediatr Neurol 2020; 105: 69–70.

    Article  Google Scholar 

  5. Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med 2020; 382: 1430–42.

    Article  CAS  Google Scholar 

  6. Yoshida Y, Yamamoto O. Ultrasonic dissection for diffuse plexiform neurofibroma. Dermatol Surg 2010; 36: 1773–4.

    Article  CAS  Google Scholar 

  7. National institutes of health consensus development conference. Neurofibromatosis. Conference statement. Arch Neurol 1988; 45: 575–8.

    Article  Google Scholar 

  8. Ehara Y, Yamamoto O, Kosaki K, Yoshida Y. Natural course and characteristics of cutaneous neurofibromas in neurofibromatosis 1. J Dermatol 2018; 45: 53–7.

    Article  Google Scholar 

  9. Wolkenstein P, Durand-Zaleski I, Moreno JC, Zeller J, Hemery F, Revuz J. Cost evaluation of the medical management of neurofibromatosis 1: a prospective study on 201patients. Br J Dermatol 2000; 142: 1166–70.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Fukuoka University School of Medicine, Fukuoka, Japan

    Monji Koga & Shinichi Imafuku

  2. Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University, Yonago, Japan

    Yuichi Yoshida & Yuko Ehara

Authors
  1. Monji Koga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuichi Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuko Ehara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shinichi Imafuku
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monji Koga.

Additional information

Disclosure

Financial support: this work was partially supported by Health and Labour Science Research Grants from the Ministry of Health, Labour and Welfare of Japan (YY and SI). Conflicts of interest: none.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koga, M., Yoshida, Y., Ehara, Y. et al. Medical costs of surgical intervention for hospitalized patients with neurofibromatosis type 1 in Japan. Eur J Dermatol 30, 618–620 (2020). https://doi.org/10.1684/ejd.2020.3869

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2020.3869

Search

Navigation